[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2107557T3 - Derivado de acido hidroxamico a base de sulfonamida aromatica. - Google Patents

Derivado de acido hidroxamico a base de sulfonamida aromatica.

Info

Publication number
ES2107557T3
ES2107557T3 ES92924883T ES92924883T ES2107557T3 ES 2107557 T3 ES2107557 T3 ES 2107557T3 ES 92924883 T ES92924883 T ES 92924883T ES 92924883 T ES92924883 T ES 92924883T ES 2107557 T3 ES2107557 T3 ES 2107557T3
Authority
ES
Spain
Prior art keywords
hydroxamic acid
cell growth
derivative
acid based
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924883T
Other languages
English (en)
Inventor
Mitsuaki Ohtani
Hitoshi Arita
Kenji Sugita
Takaharu Matsuura
Kazuhiro Shirahase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2107557T3 publication Critical patent/ES2107557T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

UN NUEVO DERIVADO DEL ACIDO HIDROXAMICO QUE CONTIENE UN COMPUESTO REPRESENTADO POR LA FORMULA GENERAL (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO COMO INGREDIENTE ACTIVO, QUE PRESENTA ACTIVIDADES PARA INHIBIR EL CRECIMIENTO CELULAR, LA VASCULARIZACION, ETC. PRESENTA ACTIVIDADES PARA INHIBIR EL CRECIMIENTO DE CELULAS HEMANGIOENDOTELIALES Y EL DESARROLLO DE UN FACTOR DE ADHESION DE LINFOCITOS Y LA DESTRANSFORMACION MEDIANTE UN GEN RAS, INHIBIENDO ASI EL CRECIMIENTO CELULAR Y SIENDO EFICAZ CONTRA LAS INFLAMACIONES Y TUMORES.
ES92924883T 1991-12-10 1992-12-07 Derivado de acido hidroxamico a base de sulfonamida aromatica. Expired - Lifetime ES2107557T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35079391 1991-12-10

Publications (1)

Publication Number Publication Date
ES2107557T3 true ES2107557T3 (es) 1997-12-01

Family

ID=18412912

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924883T Expired - Lifetime ES2107557T3 (es) 1991-12-10 1992-12-07 Derivado de acido hidroxamico a base de sulfonamida aromatica.

Country Status (10)

Country Link
US (1) US5534654A (es)
EP (1) EP0570594B1 (es)
JP (1) JP3342485B2 (es)
KR (1) KR100236806B1 (es)
AT (1) ATE156116T1 (es)
DE (1) DE69221290T2 (es)
DK (1) DK0570594T3 (es)
ES (1) ES2107557T3 (es)
GR (1) GR3024740T3 (es)
WO (1) WO1993012075A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0754682T3 (da) * 1994-04-06 2002-02-04 Western Therapeutics Inst D Aminostilbazolderivat og lægemiddel
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
AR011057A1 (es) * 1997-01-08 2000-08-02 Smithkline Beecham Corp Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
JP2001026506A (ja) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd スルホンアミド誘導体
US6586617B1 (en) * 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
WO2000069465A1 (fr) * 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
KR20070053362A (ko) 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
AU2001248201B2 (en) * 2000-04-13 2006-12-14 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
EP1752446A3 (en) * 2000-04-13 2007-03-21 HSC Research and Development Limited Partnership Compounds for modulating cell proliferation
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
ES2257441T3 (es) * 2000-09-29 2006-08-01 Topotarget Uk Limited Compuestos de acido carbonico que comprenden un enlace amino como inhibidores hdac.
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) * 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1572678A4 (en) * 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
EP1599449A2 (en) * 2003-02-25 2005-11-30 TopoTarget UK Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
KR101130556B1 (ko) * 2004-03-11 2012-03-30 4에스체 악티엔게젤샤프트 Ｈｄａｃ 억제제로서의 설포닐피롤
CA2560584A1 (en) 2004-03-26 2005-10-06 Hsc Research And Development Limited Partnership Novel compounds for modulating cell proliferation
WO2006075888A1 (en) * 2005-01-14 2006-07-20 Sk Corporation Oxazole hydroxamic acid derivatives and use thereof
MX2007010561A (es) 2005-03-15 2008-02-22 Nycomed Gmbh N-sulfonilpirroles y su uso como inhibidores de la histona desacetilasa.
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
JP5054671B2 (ja) * 2005-04-07 2012-10-24 フォーエスシー アクチエンゲゼルシャフト ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
PL1928872T3 (pl) 2005-09-21 2012-08-31 4Sc Ag Nowe sulfonylopirole jako inhibitory HDAC
CA2622670A1 (en) 2005-09-21 2007-04-12 Nycomed Gmbh Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
RU2008135979A (ru) 2006-02-07 2010-03-20 Астеллас Фарма Инк. (Jp) Соединения гидроксиакрилаимда
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101417967A (zh) * 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
EP2100878A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
EP2340242A4 (en) 2008-10-22 2012-04-04 Acucela Inc COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
MX2014007969A (es) * 2011-12-29 2015-02-10 Pharmacyclics Inc Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
CR20160272A (es) 2013-12-18 2016-08-16 Glaxosmithkline Ip Dev Ltd REGULADORES DE Nrf2
SG11201707418WA (en) 2015-03-13 2017-10-30 Forma Therapeutics Inc Alpha-cinnamide compounds and compositions as hdac8 inhibitors
JP6786527B2 (ja) 2015-06-15 2020-11-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター
CN108112251B (zh) 2015-06-15 2021-03-05 葛兰素史克知识产权发展有限公司 Nrf2调节剂
JP2018529745A (ja) 2015-10-06 2018-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのビアリールピラゾール
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
KR20240047155A (ko) 2022-10-04 2024-04-12 유영훈 열선용 커넥션 키트

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2984077B2 (ja) * 1990-04-19 1999-11-29 塩野義製薬株式会社 スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体

Also Published As

Publication number Publication date
KR100236806B1 (ko) 2000-01-15
GR3024740T3 (en) 1997-12-31
JP3342485B2 (ja) 2002-11-11
WO1993012075A1 (en) 1993-06-24
DE69221290T2 (de) 1998-01-15
DK0570594T3 (es) 1997-08-25
US5534654A (en) 1996-07-09
KR930703243A (ko) 1993-11-29
EP0570594B1 (en) 1997-07-30
DE69221290D1 (de) 1997-09-04
ATE156116T1 (de) 1997-08-15
EP0570594A1 (en) 1993-11-24
EP0570594A4 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
ES2107557T3 (es) Derivado de acido hidroxamico a base de sulfonamida aromatica.
NO950297D0 (no) Prolinamidderivater
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
NO900306L (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
AU593736B2 (en) Novel intermediates
ES8801217A1 (es) Un procedimiento para la preparacion de un derivado de acido 5-imidazolcarboxilico
ES2109993T3 (es) Derivados de 4-desoxi-4-epipodofilotoxina o sus sales farmaceuticamente aceptables.
ATE126796T1 (de) Quinazolinderivate und ihre herstellung.
AU7415387A (en) Imidazolesulfonamide derivatives and herbicides
ES2053946T3 (es) Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-onas.
EP1000923A4 (en) CYCLOPENTEN DERIVATIVES
EP1026162A4 (en) ANTI-RHUMATISMAL AGENT
DK0676399T3 (da) Methotrexaderivater
MX9206930A (es) Nuevos compuestos
IT1216104B (it) Peptidi ad attivita' farmaceutica.
DE69627519D1 (de) Sesquiterpen-derivate mit antiviraler aktivität
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
ATE192141T1 (de) Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung
DK0466662T3 (da) 6,7-Disubstituerede-2-aminotetraliner, der er aktive som immunmodulatorer, samt farmaceutiske præparater indeholdende sådanne forbindelser
ATE154243T1 (de) Hemmstoff der blutgefässhypertrophie
ES2045335T3 (es) Un procedimiento para la preparacion de nuevas s-difluorometilhomocisteinas.
JPS643164A (en) Imine compound
TH13254A (th) ฟธาแลซีนชนิดใหม่ที่ประกอบด้วยอีเธอร์หรือไธโออีเธอร์ที่ตำแหน่ง 1-และกรรมวิธีการเตรียม

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 570594

Country of ref document: ES